Organisation paid for research Program year 2025 Source: CMS Open Payments

Henry Ford Health System

Neither a doctor nor a teaching hospital

Research payments

$3,849,058

660 payments

Through program year 2025, Henry Ford Health System is reported as receiving $3,849,058 in research payments, across 660 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $467,593 43
2024 Research $369,342 113
2023 Research $443,828 132
2022 Research $1,390,827 75
2021 Research $375,873 66
2020 Research $469,271 80
2019 Research $332,324 151

Breakdown

Who paid Research payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $2,090,658 219 payments
  2. Bayer HealthCare Pharmaceuticals Inc. $382,052 46 payments
  3. Amgen Inc. $182,284 22 payments
  4. Taiho Oncology, Inc. $170,467 47 payments
  5. Eisai Inc. $142,909 17 payments
  6. ViiV Healthcare Company $102,295 33 payments
  7. Ge Healthcare $89,698 9 payments
  8. Merck Sharp & Dohme Corporation $86,330 12 payments
  9. Genmab U.S., Inc. $77,644 2 payments
  10. Novartis Pharmaceuticals Corporation $71,206 10 payments
Studies the money was for Research payments · program years 2019–2025
  1. Understanding Pruritus in Patients With Chronic Hepatitis B and C $1,111,107 9 payments
  2. A Phase Iib Multi-Center, Randomised, Open Label Study to Assess the E $193,439 33 payments
  3. open-label Phase 1 first-in-human dose escalation and expansion study to evaluate the safety tolerability maximum tolerated or administered dose pharmacokinetics pharmacodynamics and tumor response profile of the ILDR2 function-blocking antibody BAY1905254 in patients with advanced solid tumors $180,086 18 payments
  4. A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Subjects With Low CA125 Platinum-Sensitive Ovarian Cancer $110,236 11 payments
  5. A Phase 2 Study of Futibatinib in Combination With PD-1 Antibody-based Standard of Care Therapy in Patients With Solid Tumors. $104,253 4 payments
  6. PH 3 HIV Two-Year Non-Inferiority Compared to Standard of Care Safety/ $94,531 30 payments
  7. Effect of a newer generation absorbent with or without an anesthesia delivery system data analytics application to reduce the cost and environmental impact of inhaled anesthetics $85,198 7 payments
  8. Study name not reported $84,509 2 payments
  9. Implementing Pruritus Assessment Into the Routine Clinical Care of Pat $84,509 1 payment
  10. A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination With Anti-cancer Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With an Immune Checkpoint Inhibitor $77,644 2 payments
What the money was spent on Research payments · program years 2019–2025
  1. Other $25,000 1 payment
  2. Patient care $3,176 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record